Additionally, the use of combination chemotherapy was limited to patients with MGMT promoter methylation, which is widely recognized as positive predictive marker due to the increased effectiveness of chemotherapy in glioma therapy [53,54,55] and demanded as an inclusion criterion for the NOA09/CeTeG trial. The gene discussed is MGMT; the disease is central nervous system cancer.